(Q52203788)

27 April 2018

title

The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. (English)

1 reference

27 April 2018

0 references

O Valverde

1

1 reference

27 April 2018

M C Fournie-Zaluski

series ordinal

2

1 reference

27 April 2018

B P Roques

series ordinal

3

1 reference

27 April 2018

R Maldonado

series ordinal

4

1 reference

27 April 2018

publication date

1 January 1996

1 reference

27 April 2018

number of pages

8

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

27 April 2018

volume

123

1 reference

27 April 2018

page(s)

119-126

1 reference

27 April 2018

issue

2

1 reference

27 April 2018

https://scigraph.springernature.com/pub.10.1007/bf02246168

exact match

0 references

cites work

Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02246168

Stimulant effects of enkephalin microinjection into the dopaminergic A10 area

21 January 2018

1 reference

12 December 2020

Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats

1 reference

12 December 2020

Rewarding properties of beta-endorphin as measured by conditioned place preference.

1 reference

12 December 2020

Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide.

1 reference

12 December 2020

Anatomically distinct opiate receptor fields mediate reward and physical dependence.

1 reference

12 December 2020

Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins

1 reference

12 December 2020

Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.

1 reference

12 December 2020

Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors.

1 reference

12 December 2020

CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.

1 reference

12 December 2020

The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice

1 reference

12 December 2020

Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats.

1 reference

12 December 2020

Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins

1 reference

12 December 2020

Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning

1 reference

12 December 2020

Drug reinforcement studied by the use of place conditioning in rat

1 reference

12 December 2020

6-OHDA lesions of the ventral tegmental area block morphine-induced but not amphetamine-induced facilitation of self-stimulation.

1 reference

12 December 2020

Regional distribution of calcitonin gene-related peptide-, substance P-, cholecystokinin-, Met5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal caps

1 reference

12 December 2020

Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice

1 reference

12 December 2020

Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses.

1 reference

12 December 2020

Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine

1 reference

12 December 2020

Opposite motivational effects of endogenous opioids in brain and periphery

1 reference

12 December 2020

Aversive and appetitive properties of anxiogenic and anxiolytic agents.

1 reference

12 December 2020

Action of drugs of abuse on brain reward systems

1 reference

12 December 2020

In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding

1 reference

12 December 2020

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

1 reference

12 December 2020

Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.

1 reference

12 December 2020

Blockade of morphine reward through the activation of kappa-opioid receptors in mice

1 reference

12 December 2020

Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation

1 reference

12 December 2020

"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes

1 reference

12 December 2020

Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain

1 reference

12 December 2020

Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway

1 reference

12 December 2020

Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology

1 reference

12 December 2020

Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists

1 reference

12 December 2020

Evidence for the Neuropeptide Cholecystokinin as an Antagonist of Opiate Analgesia

1 reference

12 December 2020

Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists.

1 reference

12 December 2020

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

1 reference

12 December 2020

Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release

1 reference

12 December 2020

Enkephalinase inhibition facilitates sexual behavior in the male rat but does not produce conditioned place preference.

1 reference

12 December 2020

Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats

1 reference

12 December 2020

Ethical guidelines for investigations of experimental pain in conscious animals

1 reference

12 December 2020

Triazolam attenuates amphetamine but not morphine conditioned place preferences

1 reference

12 December 2020

Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine

1 reference

12 December 2020

Effect of cyclosporine A on the morphine-induced place preference.

1 reference

12 December 2020

Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101

1 reference

12 December 2020

Evidence for coexistence of dopamine and CCK in meso-limbic neurones

1 reference

12 December 2020

Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02246168

1 reference

27 April 2018

PubMed ID

8741934

1 reference

27 April 2018